Measured rollout will tap the drug’s promise while navigating its complex REMS program
Cleveland Clinic will begin offering brexanolone, the first medication to treat moderate to severe postpartum depression, via a pilot program at one of its regional hospitals soon after the drug’s launch, which is expected in late June. The fast-acting neurosteroid, which received FDA approval in March under the name Zulresso
, is administered via continuous IV infusion for 60 hours in an inpatient setting.
As detailed in this earlier Consult QD post, brexanolone is a derivative of endogenous allopregnanolone, a hormone that declines after childbirth. It works as an allosteric modulator of GABA-A receptors. GABA is an inhibitory neurotransmitter and may play an important role in modulating vulnerability to depression and anxiety.
CC0 Creative Commons Pixabay
Read more at Consult QD…
The post Wondering How to Offer Brexanolone for Postpartum Depression? Here’s How We’re Piloting It appeared first on Healthier Environment Living Program.